Review Article

Oral Panax notoginseng Preparation for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials

Table 4

Adverse Events.

Study IDADs

Du and Chen 2009 [21]No abnormal changes appeared and no Ads was reported in the trial.
Ge and Zhao 2010 [22]Blood regular test, urine regular test, and blood biochemistry test had no changes compared with the previous.
Han and Chen 2008 [23]No serious Ads were reported in the trial; blood, urine, and stool routine tests, blood biochemistry test had no changes comparing with the previous.
Ji and Zhang 2003 [24]Blood, urine, and stool routine tests, and blood biochemistry test had no changes compared with the previous. No Ads was reported in the trial.
Meng 2003 [25]Reduction of blood pressure and increasement of heart rate: intervention group: 0/60; control group: 5/20. RR: 0.03. 95% CI: [0.00, 0.54].
Wei 2010 [29]Blood, urine, and stool routine tests, and blood biochemistry test had no changes compared with the previous. No Ads was reported in the trial.
Yan 2005 [30]Nausea: intervention group (1/24), control group (0/24), RR: 3.0, 95% CI: [0.13, 70.16].
Dizziness: intervention group (0/24), control group (1/24), RR: 0.33, 95% CI: [0.01, 7.80].
Vomit: intervention group (0/24), control group (1/24), RR: 0.33, 95% CI: [0.01, 7.80].
Yu 2010 [31]Erythra: intervention group (1/50), control group: (0/50). RR: 3.00; 95% CI: [0.13, 71.92].
Kuang et al. 2011 [33]No abnormal changes appeared and no Ads was reported in the trial.

Note: ADs: Adverse Events.